Generative AI for life sciences

Generative AI (GenAI) is poised to deliver a dose of adrenalin that will
revolutionize the life sciences industry. But just as companies must design
clinical trials to ensure accuracy,legitimacy, and efficacy, they must
also carefully manage the deployment of GenAI throughout the enterprise.

At Capgemini Group, we believe this technology will evolve rapidly over the next few years and have identified three phases of this evolution – exploration, augmentation, and re-invention. Now is the time for organizations to plan their generative AI strategy and explore carefully selected use cases in a controlled environment.